Stockscreener 앱 받기
0.00
100.00%
-17.11
전일 마감가:
$17.11
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$541.25M
수익:
-
순이익/손실:
$6.74M
주가수익비율:
0.00
EPS:
0.2142
순현금흐름:
$-412.70K
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$18.16
Veraxa Biotech Ag Stock (VACH) Company Profile
명칭
Veraxa Biotech Ag
전화
03477204333
주소
C/O WINSTON & STRAWN LLP, HOUSTON
Compare VACH vs LION, XXI, UMAC, CCXI, DMII
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VACH
Veraxa Biotech Ag
|
0.00 | 541.25M | 0 | 6.74M | -412.70K | 0.2142 |
LION
Lionsgate Studios Corp
|
11.15 | 3.29B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
5.45 | 3.17B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
23.53 | 1.21B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
12.81 | 735.24M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.17 | 647.19M | 0 | 8.58M | -1.11M | 0.134 |
Veraxa Biotech Ag 주식(VACH)의 최신 뉴스
Veraxa Biotech (VRXA) Insider Trading Activity 2026 - MarketBeat
VERAXA Biotech Designates Raju Willener as CFO - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener As Chief Financial Officer - menafn.com
Veraxa Biotech AG (NASDAQ: VRXA) Names Raju Willener as CFO Following De-SPAC Completion - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer - USA Today
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
VRXA Rises As Veraxa Biotech AG Draws Trader Focus - timothysykes.com
Veraxa Biotech AG Company Profile & Introduction - Moomoo
VRXA Jumps As Traders Focus On Biotech Breakout Setup - timothysykes.com
VRXA Should I Buy - Intellectia AI
VERAXA Biotech Appoints Veteran Finance Executive Raju Willener as CFO to Drive Capital Strategy and Oncology Pipeline Growth - citybuzz -
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Veraxa Biotech names Raju Willener as chief financial officer By Investing.com - Investing.com Australia
Veraxa Biotech AG Announces Chief Financial Officer Changes - marketscreener.com
Veraxa Biotech stock rises after naming Raju Willener as CFO By Investing.com - Investing.com India
Veraxa Biotech stock rises after naming Raju Willener as CFO - Investing.com
Finance veteran behind CHF 30B portfolios joins Veraxa Biotech (VRXA) as CFO - Stock Titan
Veraxa Biotech names Raju Willener as chief financial officer - Investing.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer - 富途牛牛
Veraxa Biotech (VRXA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Insider Buys Additional CHF75k In Veraxa Biotech Stock - simplywall.st
Veraxa Biotech (VRXA) Stock Chart and Price History 2026 - MarketBeat
Veraxa Biotech (VRXA) director adds 50K shares in open-market buy - Stock Titan
Veraxa Biotech (VRXA) CEO now holds 5,000 ordinary shares - Stock Titan
VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation T - Benzinga
Early lab data advance Veraxa (Nasdaq: VRXA) autoimmune AOC - stocktitan.net
Veraxa and Secarna report positive early results from AOC study By Investing.com - Investing.com India
Veraxa Biotech AG - via.ritzau.dk
VERAXA Biotech Advances VXA-222 Cancer Program Beyond Discovery Phase, Strengthens IP Portfolio - citybuzz -
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
Veraxa Biotech Ag (VACH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
0.14%
자본화:
|
볼륨(24시간):